Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease
A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients
1. OBJECTIVES Primary objective to evaluate the difference of the peak oxygen uptake change (VO2 max, mL/kg/min) in amlodipine group against no CCB group at 9 months Secondary objectives To evaluate the change of sublingual…
- Trial name
- NCT01120327
- Testing
- Amlodipine
- Where
- South Korea
- Volunteers
- 211 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
ABSORB PHYSIOLOGY Clinical Investigation
The target enrollment goal for the trial was to enroll 36 subjects. However due to a challenging protocol inclusion/ exclusion criteria, only one subject was enrolled since the trial was initiated in June 2011.
- Trial name
- NCT01308346
- Testing
- Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS), XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
- Where
- 6 sites in Australia, China and 2 more
- Volunteers
- 1 people
- Sponsor
- Abbott Medical Devices
Stable Angina, Coronary Artery Disease
OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina
This study aims to evaluate whether the use of optical coherence tomography (OCT), an advanced intravascular imaging tool, can improve stent implantation results and make it possible to shorten the duration of dual antiplatelet…
- Trial name
- COMFORT-SHORT (NCT07198529)
- Testing
- Short DAPT, Standard DAPT, Extended DAPT
- Where
- South Korea
- Volunteers
- 130 people
- Sponsor
- Korea University Guro Hospital
Coronary Artery Disease
3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES).
- Trial name
- MODEL U-SES (NCT02837003)
- Testing
- Aspirin, Thienopyridine
- Where
- Japan
- Volunteers
- 1,500 people
- Sponsor
- Teikyo University
Pulmonary Artery Stenosis, Aortic Coarctation
Minima Stent System Post- Approval Study (PAS)
This Post-Approval Study is a single arm, prospective, multi-center, open-label study of patients treated with the Renata Minima Stent System in the United States.
- Trial name
- NCT06828770
- Testing
- Minima Stent System
- Where
- 15 sites in United States
- Volunteers
- 100 people
- Sponsor
- Renata Medical
Coronary Artery Disease
Non-inferiority Study Comparing Firehawk Stent With Abbott Xience Family Stent (TARGET-AC)
Purpose The TARGET All comers trial is a prospective, multicenter, randomized, two-arm, non-inferiority, open-label study with 1656 patients at 20 centers in Europe. The study is a "real world, all comers" study.
- Trial name
- NCT02520180
- Testing
- Firehawk™ stent system, Abbott Xience family Everolimus-Eluting Stent
- Where
- Denmark
- Volunteers
- 1,653 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Myocardial Ischemia, Coronary Artery Stenosis
SPIRIT PRIME Clinical Trial
To evaluate the safety and effectiveness of the XIENCE PRIME and XIENCE PRIME Long Lesion (LL) Everolimus Eluting Coronary Stent System (EECSS) in improving coronary luminal diameter in subjects with symptomatic heart disease due…
- Conditions
- Myocardial Ischemia, Coronary Artery Stenosis, Coronary Disease, Coronary Artery Disease
- Trial name
- SPIRIT PRIME (NCT00916370)
- Testing
- Core size Xience Prime, Xience Prime Long Lesion (LL)
- Where
- 62 sites in United States, Australia
- Volunteers
- 525 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
Japan-Drug Eluting Stents Evaluation; a Randomized Trial
To evaluate the procedural, short and long term clinical outcomes of the TAXUS stent compared to Cypher stent in coronary arteries of ≥ 2.5 and ≤ 3.75 mm in the reference vessel diameter with a lesion of ≤ 46 mm (by visual…
- Trial name
- J-DESsERT® (NCT00708669)
- Testing
- TAXUS stent, Cypher stent
- Where
- 122 sites in Japan
- Volunteers
- 3,500 people
- Sponsor
- Associations for Establishment of Evidence in Interventions
Coronary Artery Disease, Ischemic Heart Disease
Prospective Registry of ihtDEStiny® Coronary Stent in Regular PCI Practice
Prospective registry intended to evaluate clinical outcomes of ihtDEStiny drug eluting coronary stent.
- Trial name
- VELAZQUEZ (NCT04899141)
- Testing
- Percutaneous Coronary Intervention
- Where
- 20 sites in Portugal, Spain
- Volunteers
- 400 people
- Sponsor
- Fundación EPIC
Coronary Artery Disease, Coronary Stenosis
Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study
ULTRA is a multicenter, observational, retrospective registry, enrolling consecutive patients treated with ultrathin coronary DES (coronary stent with strut thickness < 70 um) for coronary bifurcation lesions, left main disease…
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Stent Restenosis, Left Main Coronary Artery Disease
- Trial name
- ULTRA (NCT05205148)
- Testing
- Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Coronary Artery Disease
A Study of the TAXUS Liberté Stent for the Treatment of de Novo Coronary Artery Lesions in Small Vessels
TAXUS ATLAS Small Vessel is a global, multi-center, single-arm, trial of patients with coronary arteries less than 2.5 mm in diameter who are treated with the TAXUS Liberté stent versus an historical TAXUS Express control derived…
- Trial name
- NCT00371748
- Testing
- TAXUS Liberté-SR, TAXUS™ Express2, Express2
- Where
- 25 sites in United States, New Zealand and 1 more
- Volunteers
- 261 people
- Sponsor
- Boston Scientific Corporation
Coronary Artery Disease
Effects of a rapamycIn-eluting carboNized Stent With a Completely biodEgradable polymeR Coating
Percutaneous coronary intervention with stenting may induce endothelial damage/dysfunction and inflammatory reactions, which in turn delay healing and endothelialization and may lead to the occurrence of major adverse cardiac…
- Trial name
- INERT (NCT01981304)
- Volunteers
- 50 people
- Sponsor
- University of Roma La Sapienza
Coronary Artery Disease, Atrial Fibrillation
Triple Therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation
The investigators hypothesize that reducing the duration of clopidogrel therapy from 6 months to 6 weeks after DES implantation is associated with improved clinical outcomes in patients on ASA and an oral anticoagulant.
- Trial name
- ISAR-TRIPLE (NCT00776633)
- Testing
- aspirin, clopidogrel, oral anticoagulation
- Where
- 3 sites in Denmark, Germany
- Volunteers
- 614 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Clopidogrel Use and Long-term Safety After Drug-Eluting Stents Implantation
The purpose of ZEST-LATE (Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events)…
- Trial name
- ZEST-LATE (NCT00590174)
- Testing
- Aspirin, Aspirin,Clopidogrel
- Where
- 20 sites in South Korea
- Volunteers
- 1,175 people
- Sponsor
- Seung-Jung Park
Coronary Artery Disease
The ATLANTA First in Man Study of the Catania Stent
To evaluate the short-term and mid-term safety and efficacy of the Catania coronary stent for the treatment of up to two de novo lesions in native coronary arteries.
- Trial name
- ATLANTA (NCT00799032)
- Testing
- PCI
- Where
- Italy
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- CeloNova BioSciences, Inc.
Atrial Fibrillation, Coronary Artery Disease
Safety and Efficacy of Left Atrial Appendage Closure Versus Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Drug-Eluting Stent Implantation Due to Complex Coronary Artery Disease
Comparatively analyze the safety and validity of Amplazter Cardiac Plug (ACP) device-using percutaneous left atrial appendage closure, and the medical treatment with dabigatran plus aspirin or dabigatran plus clopidogrel after…
- Trial name
- NCT02606552
- Testing
- Dabigatrain plus aspirin, Dabigatrain plus clopidogrel, Amplazter Cardiac Plug (ACP)
- Where
- South Korea
- Volunteers
- 9 people
- Sponsor
- Yonsei University
Coronary Arteriosclerosis
Left Main Coronary Artery Stenosis and Angioplasty With Taxus Stent
The purpose of this study is to determine whether percutaneous coronary angioplasty with Taxus drug eluting stent is safe and effective in the treatment of unprotected left main coronary artery disease associated to other…
- Trial name
- NCT00300157
- Testing
- Percutaneous coronary intervention with Taxus stent
- Where
- 26 sites in France
- Volunteers
- 155 people
- Sponsor
- French Cardiology Society
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Coronary Artery Disease
Nordic Bifurcation Study. How to Use Drug Eluting Stents (DES) in Bifurcation Lesions?
How to use drug eluting stents (DES) in bifurcation lesions. A strategy of routine stenting of both main vessel and side branch versus a strategy of routine main vessel stenting and optional treatment of side branch.
- Trial name
- BIFI (NCT00376571)
- Testing
- Percutaneous coronary intervention
- Where
- Denmark
- Volunteers
- 413 people
- Sponsor
- Aarhus University Hospital Skejby
Coronary Artery Stenosis, Coronary Arteriosclerosis
XIENCE V: SPIRIT WOMEN
The purpose of this Clinical Evaluation is the continued assessment of the XIENCE Everolimus Eluting Coronary Stent System (XIENCE V® and XIENCE PRIME™ EECSS) with the primary focus on clinical outcomes in the treatment of female…
- Conditions
- Coronary Artery Stenosis, Coronary Arteriosclerosis, Coronary Artery Disease, Coronary Artery Restenosis
- Trial name
- NCT00496938
- Testing
- XIENCE V®/ XIENCE PRIME™
- Where
- 95 sites in Argentina, Australia and 24 more
- Volunteers
- 1,600 people
- Sponsor
- Abbott Medical Devices